| Budget Amount *help |
¥137,670,000 (Direct Cost: ¥105,900,000、Indirect Cost: ¥31,770,000)
Fiscal Year 2014: ¥25,090,000 (Direct Cost: ¥19,300,000、Indirect Cost: ¥5,790,000)
Fiscal Year 2013: ¥26,260,000 (Direct Cost: ¥20,200,000、Indirect Cost: ¥6,060,000)
Fiscal Year 2012: ¥28,210,000 (Direct Cost: ¥21,700,000、Indirect Cost: ¥6,510,000)
Fiscal Year 2011: ¥28,340,000 (Direct Cost: ¥21,800,000、Indirect Cost: ¥6,540,000)
Fiscal Year 2010: ¥29,770,000 (Direct Cost: ¥22,900,000、Indirect Cost: ¥6,870,000)
|
|---|
| Outline of Final Research Achievements |
A G-protein coupled receptor BLT2 is expressed in epithelial cells, and important in interstinal barrier function and epidermal wound healing. Nonsteroidal anti-inflammatory drugs including aspirin delays skin wound healing by inhibiting the production of 12-HHT, a BLT2 ligand. A synthetic BLT2 agonist is a drug candidate for intractable skin ulcer in the future. Zebrafish embryogenesis requires BLT1 and BLT2. Gene knockout studies showed that BLT1 augments multiple sclerosis, and delays the recovery from spinal injury. BLT2 seems to attenuate asthmatic responses.
|
